Finance

Lists
Why is ELVN down 4.23%?
Dive Deeper
ELVN:NASDAQ
Enliven Therapeutics Inc
$46.15
-4.23%
(-2.04) 1D
Sep 23, 10:58:05 AM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ELVN...
Open
$47.84
High
$48.03
Low
$45.66
Mkt. cap
3.38B
Avg. vol.
1.20M
Volume
209.38K
52-wk high
$62.32
52-wk low
$14.78
EPS
-$1.67
Beta
0.30
Shares outstanding
73.27M
No. of employees
67
Open
$47.84
High
$48.03
Low
$45.66
Mkt. cap
3.38B
Avg. vol.
1.20M
Volume
209.38K
52-wk high
$62.32
52-wk low
$14.78
EPS
-$1.67
Beta
0.30
Shares outstanding
73.27M
No. of employees
67
News stories
From web sources and news partners
About Enliven Therapeutics Inc
CEO-
Employees67
Founded2016
HeadquartersBoulder, Colorado, United States
SectorPharmaceutical industry
Websiteimaratx.com
Analyst ratings
Based on 12 analysts giving stock ratings to ELVN in the past 3 months
Strong buy
Buy
12
Hold
0
Sell
0
12-month forecast
Based on 12 Wall Street analysts offering 12 month price targets for ELVN in the last 3 months.
Highest
Current $46.15
$82.00 (+77.68%)
Average
$73.90 (+60.13%)
Lowest
$65.00 (+40.85%)
Analyst
Recommendation
Action
Price target
Projected
Date
Andy Hsieh
William Blair
Buy
Maintained
-
-
08/22/2026
Etzer Darout
Barclays
Buy
Initiated
$78.00
+69%
08/18/2026
Salim Syed
Mizuho Securities
Buy
Maintained
$73.00
+58.2%
08/17/2026
Dara Azar
Stifel Nicolaus
Buy
Reiterated
$82.00
+77.7%
08/13/2026
Sam Slutsky
LifeSci Capital
Buy
Reiterated
$70.00
+51.7%
08/08/2026
Colleen M. Kusy
Robert W. Baird
Buy
Maintained
$75.00
+62.5%
08/06/2026
Boris Peaker
JonesTrading
Buy
Reiterated
$70.00
+51.7%
08/06/2026
Michael Schmidt
Guggenheim
Buy
Maintained
$78.00
+69%
08/05/2026
Phil Nadeau
TD Cowen
Buy
Maintained
-
-
08/05/2026
Salveen Richter
Goldman Sachs
Buy
Reiterated
$80.00
+73.3%
08/05/2026
Kaveri Pohlman
Clear Street
Buy
Reiterated
$68.00
+47.3%
08/06/2026
Robert Burns
H.C. Wainwright
Buy
Reiterated
$65.00
+40.8%
07/09/2026
Unknown Analyst
Jefferies
Buy
Maintained
$59.00
+27.8%
06/15/2026
Soumit Roy
JonesTrading
Buy
Maintained
$45.00
-2.5%
04/06/2026
Last report
Aug 5, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
-$0.49 / -$0.34
-46.27%miss
Revenue / Est. (USD)
- / 0.00
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
18.22M
21.24M
20.69M
29.00M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
6.87M
13.04M
7.14M
8.21M
Operating expense
25.10M
34.28M
27.82M
37.21M
Total operating expenses
25.10M
34.28M
27.82M
37.21M
Operating income
-25.10M
-34.28M
-27.82M
-37.21M
Other non operating income
-
-
-
-8.00K
EBT including unusual items
-20.15M
-29.67M
-23.63M
-32.48M
EBT excluding unusual items
-20.15M
-29.67M
-23.63M
-32.48M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-20.15M
-29.67M
-23.63M
-32.48M
Net profit margin
-
-
-
-
Earnings per share
-0.32
-0.48
-0.38
-0.49
Interest and investment income
4.95M
4.62M
4.20M
4.73M
Interest expense
-
-
-
-
Net interest expenses
4.95M
4.62M
4.20M
4.73M
Depreciation and amortization charges
-
-
-
-
EBITDA
-25.03M
-34.24M
-27.81M
-37.20M
Gain or loss from assets sale
-
106.00K
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps